Pariser, David M.
Hebert, Adelaide A.
Drew, Janice
Quiring, John
Gopalan, Ramanan
Glaser, Dee Anna
Clinical trials referenced in this document:
Documents that mention this clinical trial
Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials
https://doi.org/10.1007/s40257-018-0395-0
Documents that mention this clinical trial
Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials
https://doi.org/10.1007/s40257-018-0395-0
Funding for this research was provided by:
Dermira, Inc.
Article History
First Online: 30 October 2018
Compliance with Ethical Standards
:
: ATMOS-1 was conducted in the USA and Germany; ATMOS-2 was conducted in the USA. Trial protocols and informed consent forms were approved by local institutional review boards or independent ethics committees on 13 May 2015, and the first patients were enrolled in July 2015 (ATMOS-1) and August 2015 (ATMOS-2). The trials were registered on ClinicalTrials.gov on 21 August 2015 (ATMOS-1 [NCT02530281] and ATMOS-2 [NCT02530294]). Both trials were carried out in accordance with Good Clinical Practice and the Declaration of Helsinki.
: These studies were sponsored and funded by Dermira, Inc. All costs associated with the development of this manuscript were funded by Dermira, Inc.
: DMP has received honoraria for consultancy from Brickell Biotech, Inc., Biofrontera AG, Celgene, Dermira, Inc., DUSA Pharmaceuticals, Inc., LEO Pharma, Novartis, Promius Pharma, LLC, Regeneron Pharmaceuticals, Inc., Sanofi, TheraVida, Inc., and Valeant Pharmaceuticals International, Inc; honoraria for participating on an advisory board for Pfizer, Inc.; investigator grants/research funding from Abbott Laboratories; Amgen, Inc.; Brickell Biotech, Inc.; Celgene; Dermavant Sciences; Eli Lilly and Company; LEO Pharma; Merck & Co, Inc.; Novartis; Novo Nordisk A/S; Ortho Dermatologics; Peplin, Inc.; Photocure ASA; Promius Pharma, LLC; Regeneron Pharmaceuticals, Inc.; Stiefel Laboratories; and Valeant Pharmaceuticals International, Inc.; and investigator honoraria from LEO Pharma and Pfizer, Inc. AAH has received investigator research funding from Dermira, Inc. (paid to the UTHealth McGovern Medical School, Houston); advisory board honoraria from Dermira, Inc.; research funding (all monies paid to the UTHealth McGovern Medical School) from Allergan, Plc., Amgen, Inc., Cassiopea, Celgene, Dermavant Sciences, Eli Lilly and Company, Galderma S.A., GSK, Plc., LEO Pharma, Mayne Pharma, Medimetriks Pharmaceuticals, Novan, Inc., Promius Pharma, LLC, and Vanda Pharmaceuticals; honoraria from Amgen, GSK, Plc., Pfizer, Inc., and Valeant Pharmaceutics International, Inc. JD and RG are employees of Dermira, Inc. JQ is a consultant for Dermira, Inc. and an employee of QST Consultations. DAG is a consultant and investigator for Dermira, Inc. and an investigator for Allergan, ATACAMA, Brickell, Galderma, Revance, and Sienna.